Free Trial Information
BioCentury | Oct 27, 2020
Product Development

SMA data validate growth factor-targeting platform for Scholar Rock as stock price doubles

...the immuno-oncology arena. Its latent TGFβ1 inhibitor SRK-181...
Read More
BioCentury | Mar 28, 2020
Translation in Brief

17 FDA-approved drugs show activity against SARS-CoV-2; two groups seek COVID-19 patient-derived mAbs; plus NYU, Scholar Rock and LIfT-King's College

...I TGF β 1 program Scholar Rock Holding Corp. (NASDAQ:SRRK) published preclinical data on its SRK-181...
...a paper published in Science Translational Medicine , the company showed a mouse version of SRK-181...
Read More
BioCentury | Jul 11, 2019
Targets & Mechanisms

The tumor stroma rises as the newest source of immuno-oncology targets

...preclinical therapies are planning combination studies.Three of those agents -- ABBV-151 from AbbVie Inc. (NYSE:ABBV), SRK-181...
...cemiplimab-rwlc (PD-1; Regeneron Pharmaceuticals Inc. (NASDAQ:RGEN)) Solid tumors Phase I Scholar Rock Holding Corp. (NASDAQ:SRRK) SRK-181...
...in actual clinical insights, and that gives us confidence,” he said. Scholar Rock’s trial of SRK-181...
Read More
Items per page:
1 - 3 of 3